We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase 1/2 trial investigates AlloNK cell therapy and rituximab in patients with non-hodgkin lymphoma, suggesting a novel treatment approach.
No takes yet. Share an insight, caveat, or question.
Farooq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: